Chronic cough is globally prevalent across all age groups. This disorder is challenging to
treat because many pulmonary and extrapulmonary conditions can present with chronic …

Cough is one of the most common presenting symptoms of COVID-19, along with fever and
loss of taste and smell. Cough can persist for weeks or months after SARS-CoV-2 infection …

Background Gefapixant is an oral P2X 3 receptor antagonist that has previously shown
efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore …

The increasing number of coronavirus disease 2019 (COVID-19) infections have highlighted
the long-term consequences of severe acute respiratory syndrome coronavirus 2 (SARS …

Chronic cough is defined in adults as a cough that lasts for≥ 8 weeks. When it proves
intractable to standard-of-care treatment, it can be referred to as refractory chronic cough …

Objective To delineate the full phenotypic spectrum, discriminative features, piloting
longitudinal progression data, and sample size calculations of replication factor complex …

Communication problems (eg, dysphonia, dysfluency and language and articulation
disorders), swallowing disorders (dysphagia and globus), cough and upper airway …

Background: Patients with serious respiratory illness and their caregivers suffer
considerable burdens, and palliative care is a fundamental right for anyone who needs it …

Introduction: Emerging evidence suggests that long-term pulmonary symptoms and
functional impairment occurs in a proportion of individuals following SARS-CoV-2 infection …

Importance Gefapixant represents an emerging therapy for patients with refractory or
unexplained chronic cough. Objective To evaluate the efficacy and tolerability of gefapixant …